Sarmad Sadeghi, MD
Medical Oncology · Los Angeles, CANPI 1316104797
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,160 of the $9,478 with a category attached, or 65.0%. 6 manufacturers reported payments, led by Pfizer at 48.0% of the total. Reporting peaked in 2019 at $6,290 and has fallen 99.7% since, to $18 in 2024.
Across 19 payments — averaging $498.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$5K
- Janssen Scientific Affairs, LLC$3K
- Seagen Inc.$2K
- Merck$115
- Comsort, Inc$100
- Bayer$27
Across 236 payments — averaging $110,610 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$19.5M
- Merck$6.5M
- Eisai Inc.$112K
- Takeda Pharmaceuticals U.S.A., Inc.$5K
What the payments were for
- Consulting fees$6,16065%
- Speaking & faculty fees$1,60017%
- Travel & lodging$1,23013%
- Food & beverage$4435%
- Education$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 10 | $4,546 |
| Janssen Scientific Affairs, LLC | 4 | $3,190 |
| Seagen Inc. | 1 | $1,500 |
| Merck | 1 | $115 |
| Comsort, Inc | 1 | $100 |
| Bayer | 2 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,478 in reported general payments places this provider in the 60th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Los Angeles
- Stephen LiuLos Angeles$750K
- Jacek PinskiLos Angeles$672K
- Mark AgulnikLos Angeles$303K
- Heinz-Josef LenzLos Angeles$185K
- Syma IqbalLos Angeles$178K
- Anthony El-KhoueiryLos Angeles$156K
- David QuinnLos Angeles$134K
- David TranLos Angeles$128K
- Afsaneh BarziLos Angeles$107K
- Stephen SherwinSan Francisco$6.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.